BR112014015753A8 - derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção - Google Patents
derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invençãoInfo
- Publication number
- BR112014015753A8 BR112014015753A8 BR112014015753A BR112014015753A BR112014015753A8 BR 112014015753 A8 BR112014015753 A8 BR 112014015753A8 BR 112014015753 A BR112014015753 A BR 112014015753A BR 112014015753 A BR112014015753 A BR 112014015753A BR 112014015753 A8 BR112014015753 A8 BR 112014015753A8
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- pharmaceutical composition
- present
- polymer derivative
- chitosan polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591293P | 2012-01-27 | 2012-01-27 | |
| US201261670665P | 2012-07-12 | 2012-07-12 | |
| PCT/EP2013/051279 WO2013110681A1 (en) | 2012-01-27 | 2013-01-24 | Chitosan covalently linked with small molecule integrin antagonist for targeted delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014015753A2 BR112014015753A2 (pt) | 2017-06-13 |
| BR112014015753A8 true BR112014015753A8 (pt) | 2017-07-04 |
Family
ID=47603735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014015753A BR112014015753A8 (pt) | 2012-01-27 | 2013-01-24 | derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20130197205A1 (pt) |
| EP (1) | EP2806896B1 (pt) |
| JP (1) | JP6230199B2 (pt) |
| KR (1) | KR20140120316A (pt) |
| CN (1) | CN104039356B (pt) |
| BR (1) | BR112014015753A8 (pt) |
| CA (1) | CA2854251A1 (pt) |
| DK (1) | DK2806896T3 (pt) |
| HK (1) | HK1201747A1 (pt) |
| MX (1) | MX2014008404A (pt) |
| RU (1) | RU2014132564A (pt) |
| WO (1) | WO2013110681A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9447035B2 (en) * | 2012-01-27 | 2016-09-20 | Hoffmann-La Roche Inc. | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 |
| CA2919088A1 (en) | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
| MX2021005050A (es) | 2018-10-30 | 2021-06-15 | Gilead Sciences Inc | Derivados de quinolina como inhibidores de integrina alfa4beta7. |
| WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| JP7214882B2 (ja) | 2018-10-30 | 2023-01-30 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体 |
| JP2022543465A (ja) | 2019-08-14 | 2022-10-12 | ギリアード サイエンシーズ， インコーポレイテッド | α４β７インテグリンの阻害のための化合物 |
| CN115073311B (zh) * | 2022-03-23 | 2023-05-23 | 河南大学 | 一种高效制备n,n′-二（2羟乙基）苯胺的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US622901A (en) * | 1899-04-11 | Machine for making tufted fabrics | ||
| US5486140A (en) | 1993-10-21 | 1996-01-23 | Venturedyne, Ltd. | Variable air volume terminal unit with exterior insulation |
| SE9402528D0 (sv) | 1994-07-19 | 1994-07-19 | Astra Ab | Hårdvävnadsstimulerande med el |
| US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
| JP2010503640A (ja) | 2006-09-15 | 2010-02-04 | エフエムシー バイオポリマー エイエス | オリゴヌクレオチド非ウイルスデリバリーシステム |
| KR100825519B1 (ko) * | 2007-01-05 | 2008-04-25 | 주식회사 바이오폴리메드 | 키토산 기재 고분자 접합체 및 그 제조방법 |
| CA2729923A1 (en) | 2007-07-06 | 2009-01-15 | Aarhus Universitet | Dehydrated chitosan nanoparticles |
| WO2009012786A2 (en) | 2007-07-23 | 2009-01-29 | Aarhus Universitet | Nanoparticle-mediated treatment for inflammatory diseases |
| CN101293933B (zh) | 2008-06-17 | 2011-05-04 | 浙江大学 | 聚乙二醇修饰壳寡糖脂肪酸嫁接物及制备方法和应用 |
| CA2984026C (en) | 2008-10-09 | 2020-02-11 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| US20120040004A1 (en) * | 2009-01-28 | 2012-02-16 | Region Midtjylland | Treatment of radiation-induced fibrosis |
-
2013
- 2013-01-24 CN CN201380004563.1A patent/CN104039356B/zh active Active
- 2013-01-24 DK DK13701252.2T patent/DK2806896T3/en active
- 2013-01-24 MX MX2014008404A patent/MX2014008404A/es unknown
- 2013-01-24 WO PCT/EP2013/051279 patent/WO2013110681A1/en active Application Filing
- 2013-01-24 CA CA2854251A patent/CA2854251A1/en not_active Abandoned
- 2013-01-24 KR KR1020147021109A patent/KR20140120316A/ko not_active Application Discontinuation
- 2013-01-24 BR BR112014015753A patent/BR112014015753A8/pt not_active Application Discontinuation
- 2013-01-24 EP EP13701252.2A patent/EP2806896B1/en active Active
- 2013-01-24 JP JP2014553708A patent/JP6230199B2/ja active Active
- 2013-01-24 US US13/748,642 patent/US20130197205A1/en not_active Abandoned
- 2013-01-24 RU RU2014132564A patent/RU2014132564A/ru not_active Application Discontinuation
- 2013-01-24 US US14/373,669 patent/US20150306130A1/en not_active Abandoned
-
2015
- 2015-03-09 HK HK15102355.8A patent/HK1201747A1/xx unknown
-
2017
- 2017-11-14 US US15/812,406 patent/US11491178B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2854251A1 (en) | 2013-08-01 |
| JP6230199B2 (ja) | 2017-11-15 |
| US11491178B2 (en) | 2022-11-08 |
| RU2014132564A (ru) | 2016-03-20 |
| BR112014015753A2 (pt) | 2017-06-13 |
| US20150306130A1 (en) | 2015-10-29 |
| JP2015504958A (ja) | 2015-02-16 |
| CN104039356B (zh) | 2018-08-17 |
| US20130197205A1 (en) | 2013-08-01 |
| HK1201747A1 (en) | 2015-09-11 |
| KR20140120316A (ko) | 2014-10-13 |
| EP2806896B1 (en) | 2018-01-03 |
| EP2806896A1 (en) | 2014-12-03 |
| DK2806896T3 (en) | 2018-03-05 |
| US20180099005A1 (en) | 2018-04-12 |
| CN104039356A (zh) | 2014-09-10 |
| WO2013110681A1 (en) | 2013-08-01 |
| MX2014008404A (es) | 2014-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1215378A1 (zh) | 藥物組合物、治療方法及其用途 | |
| BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
| BR112014015753A2 (pt) | derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção | |
| BR112015000437A2 (pt) | imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula | |
| BR112015001098A2 (pt) | composto, composição farmacêutica e método para o tratamento de uma condição de doença. | |
| BR112013011968A2 (pt) | composição farmacêutica, métodos de tratamento e usos da mesma | |
| BR112015007061A2 (pt) | composto, composição farmacêutica e método para tratar uma condição ou distúrbio dependente de apkc em um paciente | |
| BR112015000441A2 (pt) | imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22 | |
| BR112014025726A2 (pt) | mecanismo, sistema e método para tratamento endodôntico | |
| BR112014028647A2 (pt) | composições e métodos para modulação da expressão de bdnf | |
| BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
| IL238662A (en) | Bandostatin derivatives, containing them and used to treat cancer | |
| BR112015000439A2 (pt) | imunoconjugado , formulação farmacêutica e métodos de tratamento de um indivíduo e de inibição da proliferação | |
| BR112013014583A2 (pt) | composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila | |
| PL2672966T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
| RS61827B1 (sr) | Farmaceutska kompozicija, postupci za lečenje i njihova primena | |
| BR112014032053A2 (pt) | composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção | |
| BR112014031896A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um distúrbio | |
| BR112014031512A2 (pt) | composição cosmética e método para o tratamento cosmético. | |
| EP2842568A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF TYPE I DIABETES AND THE USE THEREOF | |
| BR112014031899A8 (pt) | composto, composição farmacêutica, e, método para tratamento de um distúrbio | |
| BR112014022694A2 (pt) | novos métodos e composições para o tratamento de doença | |
| BR112014025339A8 (pt) | método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo. | |
| BR112014003556A2 (pt) | método de tratamento de vírus, e, composição farmacêutica | |
| BR112015001843A2 (pt) | dispositivo médico, composição de matriz biodegradável e método para tratar um paciente. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), A61P 35/00 (2006.01), A61P 2 |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |